trans-AUCB (t-AUCB) is a potent, orally active, and selective soluble epoxide hydrolase (sEH) inhibitor with IC50s of 1.3 nM, 8 nM, and 8 nM for hsEH, mouse sEH, and rat sEH, respectively. It also demonstrates anti-glioma activity.
- Potent, orally active, and selective soluble epoxide hydrolase (sEH) inhibitor.
- IC50s: 1.3 nM (hsEH), 8 nM (mouse sEH), and 8 nM (rat sEH).
- Possesses anti-glioma activity.
- Suppresses U251 and U87 cell growth in a dose-dependent manner.
- Induces cell-cycle G0/G1 phase arrest in U251 and U87 cells.
- Increases phosphorylation levels of p65.
- Suppresses U251 and U87 cell growth by activating NF-jB-p65.
- Efficiently inhibits sEH activities in human glioblastoma cell lines (U251, U87) and human hepatocellular carcinoma cell line (HepG2 cells).
- Ameliorates LPS-induced hypotension in a dose-dependent manner in mice.